Gilead Sciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel O'Day
- Full Time Employees
- 17,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 333 Lakeside Drive Foster City CA United States of America 94404
- IPO Date
- Jan 22, 1992
- CIK
- 0000882095
- Website
- gilead.com
- Similar Companies
- Business
- Gilead Sciences, Inc. (Nasdaq: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, with primary focus areas including HIV/AIDS, viral hepatitis, oncology, inflammation and serious respiratory diseases. The company markets a portfolio of marketed products such as Biktarvy, Descovy, Truvada and Veklury for virology; Epclusa, Vosevi and Vemlidy for liver diseases; Trodelvy, Tecartus and Yescarta for oncology; and investigational assets across its therapeutic areas, including complete regimen single-tablet treatments for HIV, nucleotide reverse transcriptase inhibitors and NS5A/NS5B inhibitors for hepatitis C. Founded in 1987 and headquartered in Foster City, California, Gilead operates globally with facilities across North America, Europe (including international headquarters in Stockley Park, UK), Asia-Pacific (such as Japan, China and Australia) and approximately 17,000 employees worldwide. Recent strategic developments include a $32 billion U.S. investment commitment by 2030 to expand manufacturing and R&D capabilities, highlighted by the September 2025 groundbreaking of a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City projected to create thousands of jobs; an up-to-$400 million acquisition in November 2025 of Sprint Bioscience's preclinical TREX1 oncology immunotherapy program; a $350 million buyout in August 2025 of Interius BioTherapeutics by subsidiary Kite Pharma to advance in vivo CAR-T cell therapies for cancer; a January 2025 strategic partnership with LEO Pharma acquiring rights to preclinical oral STAT6 inhibitors and targeted protein degraders for inflammatory diseases; and an expanded agreement with Cognizant in early 2025 to enhance productivity through advanced technologies.
Company News
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Archer Investment Corp Takes Position in Gilead Sciences, Inc. $GILD
BNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILD
Beacon Pointe Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
Bamco Inc. NY Sells 12,000 Shares of Gilead Sciences, Inc. $GILD
US FDA approves Gilead's once-daily combination pill for HIV treatment
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
3 Dividend Stocks to Hold for the Next 10 Years
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD
Allworth Financial LP Invests $5.96 Million in Gilead Sciences, Inc. $GILD